Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Patients develop central obesity with fat redistribution to the trunk, face, and dorsocervical region, alongside muscle wasting in the extremities
Through weight reduction, GLP-1 medications can reduce or eliminate sleep apnea and lower blood pressure
Coya Therapeutics (NASDAQ: COYA) shares nosedived 35% between Monday and Wednesday after the company announced mixed results from its placebo-controlled, 38-patient Phase II trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimers disease
Generally, anti-obesity therapies have displayed modest efficacy and mixed safety profiles, leaving a clear unmet clinical need that requires addressing
US$ 23.60
US$ 25.70
US$ 21.90
